SCHEMBL24569368

SCHEMBL24569368

C=C1C(=O)N(C(=O)OC(C)(C)C)C[C@@H]1C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.36
▸ CHRM2 P08172 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.33
▸ KDM1A O60341 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ DDB1 Q16531 1/20 0.33
▸ CRBN Q96SW2 1/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HSD11B1 P28845 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ELANE P08246 1/20 0.32
▸ GPR119 Q8TDV5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24569422 1.00 NR1H2 (0.36) NR1H2CHRM2CHRM1CHRM3KDM4E
SCHEMBL24570200 0.80 NAMPT (0.34) NR1H2CHRM2CHRM1CHRM3KDM4E
SCHEMBL31133629 0.80 NR1H2 (0.33) NR1H2CHRM2CHRM1CHRM3KDM4E
SCHEMBL2729399 0.77 CHRM2 (0.40) NR1H2CHRM2CHRM1CHRM3KDM4E
SCHEMBL30661519 0.77 CHRM2 (0.40) NR1H2CHRM2CHRM1CHRM3KDM4E
SCHEMBL30692231 0.77 CHRM2 (0.40) NR1H2CHRM2CHRM1CHRM3KDM4E
SCHEMBL30692229 0.75 ELANE (0.38) NR1H2CHRM2CHRM1CHRM3KDM4E
SCHEMBL24569594 0.75 NR1H2 (0.38) NR1H2CHRM2CHRM1CHRM3KDM4E
SCHEMBL8445535 0.74 ELANE (0.33) NR1H2CHRM2CHRM1CHRM3KDM1A
SCHEMBL15687962 0.72 BRD4 (0.38) KDM4EKDM1AMAPTTHRBDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116921-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2024-04-11 — — US disclosed
EP-4267137-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2023-11-01 — — EP disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 — — WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116921-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ERBB2, FGFR2, ERBB3 NR1H2 3911/4885CHRM2 4424/4885CHRM1 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback